CARLSBAD, Calif., July 11, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE - News) today announced that it will accelerate development of its Ion Torrent Semiconductor technology for a broad set of proteomic and antibody-based applications after passing internal Life Technologies R&D milestones.
Proteomic and antibody-based technologies are used prevalently across multiple addressable markets in research, applied sciences and clinical diagnostics. Research and development teams across Life Technologies are focused on new product development in these addressable markets.
Life Technologies anticipates potential initial applications in transplant diagnostics (human leukocyte antigen - HLA), microbiology, and food safety testing, but additional application areas may be explored internally or via partnership.
"Our internal efforts are accelerating the research and development to build products which use Ion Torrent to detect signals inherent in the binding complexes with proteins, antigens and antibodies," said Alan Sachs, chief scientific officer of Life Technologies.Life Technologies is committed to continuing to invest in the development of these proteomic and antibody-based applications for the Ion Torrent technology and in expanding its intellectual property portfolio in this arena. Antibody / antigen complexes and proteins can be combined with bead-based sample-preparation technologies used on Ion Torrent's Semiconductor Sequencing technologies. The sensitive signal detection available on the Ion Torrent semiconductor chip works by recognizing electrical and ionic changes through a sensor, and the currently available products are being used with nucleic acids. "In disease areas like Transplant Diagnostics and Cancer, having the ability to analyze proteins and genes on the same system, in the same lab, brings convenience, better turnaround time and allows for democratization of critical information for better patient management," said Ronnie Andrews, president of Medical Sciences at Life Technologies. The Ion PGM system is currently for research purposes only and is not intended for diagnostic uses.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV